Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
MISSISSAUGA, Ontario, 01 avr. 2026 (GLOBE NEWSWIRE) -- BioSyent inc. (« BioSyent », Bourse de croissance TSX : RX) est heureuse d’annoncer que FeraMAXMD a été désigné supplément de fer en vente...
-
TORONTO, April 01, 2026 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma” or the “Company”), a biopharmaceutical company dedicated to building a...
-
Distribution agreement to enhance channel partner expansion across five U.S. states The collaboration is expected to support adoption of advanced 3D imaging within orthopedic practices and surgical...
-
Bezuclastinib NDA submitted under the FDA’s RTOR program based on positive results from Phase 3 PEAK trial; bezuclastinib previously granted Breakthrough Therapy Designation in GISTBezuclastinib...
-
Exclusive licensing arrangements expand RemoniHealth's Vision-as-a-Service platform; 150,000 monitoring encounters completed.
-
Sydney, April 01, 2026 (GLOBE NEWSWIRE) -- New global report reveals men and young adults driving soaring usage of wellness technologies BON CHARGE™ Global Wellness Tech Trend Report...
-
- Poster on previously shared positive results from DELIVER clinical trial in Duchenne muscular dystrophy (DMD) contextualizes observed clinical measures of functional improvement for managed care...
-
Foundation for Sarcoidosis Research Launches See Sarcoidosis Campaign for April's Awareness Month
-
Pasithea Therapeutics Announces Grant of Fast Track Designation by FDA to PAS-004 for Treatment of NF1 Associated Plexiform Neurofibromas
-
Axsome obtains exclusive global rights to balipodect, a potentially first-in-class selective phosphodiesterase 10A inhibitor Acquisition further expands Axsome’s industry-leading CNS portfolio with a...